title: Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation.
abstract: BACKGROUND
  In rodent models of Parkinson's disease (PD), dopamine neuron loss is accompanied by increased expression of angiotensin II (AngII), its type 1 receptor (AT1), and NADPH oxidase (Nox) in the nigral dopamine neurons and microglia. AT1 blockers (ARBs) stymie such oxidative damage and neuron loss. Whether changes in the AngII/AT1/Nox4 axis contribute to Parkinson neuropathogenesis is unknown. Here, we studied the distribution of AT1 and Nox4 in dopamine neurons in two nigral subregions: the less affected calbindin-rich matrix and the first-affected calbindin-poor nigrosome 1 of three patients, who were clinically asymptomatic, but had nigral dopamine cell loss and Braak stages consistent with a neuropathological diagnosis of PD (prePD). For comparison, five clinically- and neuropathologically-confirmed PD patients and seven age-matched control patients (AMC) were examined.
  
  
  RESULTS
  AT1 and Nox4 immunoreactivity was noted in dopamine neurons in both the matrix and the nigrosome 1. The total cellular levels of AT1 in surviving dopamine neurons in the matrix and nigrosome 1 declined from AMC>prePD>PD, suggesting that an AngII/AT1/Nox4 axis orders neurodegenerative progression. In this vein, the loss of dopamine neurons was paralleled by a decline in total AT1 per surviving dopamine neuron. Similarly, AT1 in the nuclei of surviving neurons in the nigral matrix declined with disease progression, i.e., AMC>prePD>PD. In contrast, in nigrosome 1, the expression of nuclear AT1 was unaffected and similar in all groups. The ratio of nuclear AT1 to total AT1 (nuclear + cytoplasmic + membrane) in dopamine neurons increased stepwise from AMC to prePD to PD. The proportional increase in nuclear AT1 in dopamine neurons in nigrosome 1 of prePD and PD patients was accompanied by elevated nuclear expression of Nox4, oxidative damage to DNA, and caspase-3-mediated cell loss.
  
  
  CONCLUSIONS
  Our observations are consistent with the idea that AngII/AT1/Nox4 axis-mediated oxidative stress gives rise to the dopamine neuron dysfunction and loss characteristic of the neuropathological and clinical manifestations of PD and suggest that the chance for a neuron to survive increases in association with lower total as well as nuclear AT1 expression. Our results support the need for further evaluation of ARBs as disease-modifying agents in PD.
authors: W Michael
authors: WM
authors: Zawada
authors: Robert E
authors: RE
authors: Mrak
authors: JoAnn
authors: J
authors: Biedermann
authors: Quinton D
authors: QD
authors: Palmer
authors: Stephen M
authors: SM
authors: Gentleman
authors: Orwa
authors: O
authors: Aboud
authors: W Sue T
authors: WS
authors: Griffin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000804:Angiotensin II / Q000378:metabolism*; D016022:Case-Control Studies; D053148:Caspase 3 / Q000378:metabolism*; D018450:Disease Progression; D059290:Dopaminergic Neurons / Q000378:metabolism*; D005260:Female; D006151:Guanosine / Q000378:metabolism*; D006801:Humans; D008297:Male; D019255:NADPH Oxidases / Q000378:metabolism*; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology*; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism
chemical_list: D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; D006151:Guanosine; D019255:NADPH Oxidases; D053148:Caspase 3
references: Acta Neuropathol. 2009 Jun;117(6):635-52
references: 19330340
references: Brain Struct Funct. 2013 Mar;218(2):373-88
references: 22407459
references: Eur J Neurosci. 2010 Nov;32(10):1695-706
references: 20964730
references: Eur J Pharmacol. 1996 Feb 22;297(3):299-306
references: 8666063
references: Hypertension. 2014 Mar;63(3):572-9
references: 24343120
references: Genes Cells. 2005 Dec;10(12):1139-51
references: 16324151
references: BMJ. 2010;340:b5465
references: 20068258
references: PLoS One. 2014;9(6):e98961
references: 24910980
references: Aging Dis. 2011 Jun;2(3):257-74
references: 22396877
references: J Biol Chem. 2010 Jul 16;285(29):22338-49
references: 20463030
references: PLoS One. 2013;8(8):e70951
references: 23940672
references: J Neuroinflammation. 2011;8:129
references: 21975039
references: Brain. 1999 Aug;122 ( Pt 8):1421-36
references: 10430829
references: Dev Neurosci. 2013;35(4):293-305
references: 23751520
references: Front Endocrinol (Lausanne). 2013 Oct 25;4:158
references: 24298267
references: Science. 1971 Jun 11;172(3988):1138-9
references: 4324923
references: Curr Gerontol Geriatr Res. 2012;2012:170276
references: 22454637
references: Curr Neuropharmacol. 2013 Mar;11(2):209-17
references: 23997755
references: Ann Neurol. 1992 Sep;32(3):339-44
references: 1416803
references: J Neurochem. 2009 Apr;109(2):656-69
references: 19245663
references: Auton Neurosci. 2013 Apr;175(1-2):85-92
references: 23466041
references: EMBO J. 2009 Dec 16;28(24):3785-98
references: 19927119
references: J Comp Neurol. 1991 Oct 8;312(2):291-8
references: 1748734
references: Brain Res. 1993 Jun 11;613(2):221-9
references: 7514480
references: Rejuvenation Res. 2010 Apr-Jun;13(2-3):195-201
references: 20370487
references: Nat Med. 2014 Aug;20(8):881-5
references: 25038828
references: Neurobiol Aging. 2007 Apr;28(4):555-67
references: 16621167
references: Cell. 1986 Jun 6;45(5):699-709
references: 3518946
references: Free Radic Biol Med. 2013 Jan;54:125-34
references: 23022406
references: Curr Opin Cell Biol. 2014 Jun;28:16-27
references: 24503411
references: Zhonghua Yi Xue Za Zhi. 2012 Oct 23;92(39):2743-6
references: 23290159
references: Mol Neurodegener. 2007 Jan 15;2:1
references: 17224059
references: Hypertension. 1996 Nov;28(5):818-24
references: 8901829
references: Exp Neurol. 2002 May;175(1):1-9
references: 12009755
references: Clin Sci Mol Med Suppl. 1976 Dec;3:399s-402s
references: 1071653
references: Neurosci Lett. 1979 Dec;15(2-3):153-8
references: 530525
references: Am J Physiol Cell Physiol. 2014 Apr 15;306(8):C736-44
references: 24401846
references: Acta Neuropathol Commun. 2013;1:41
references: 24252240
references: Neurobiol Aging. 2012 Jan;33(1):204.e1-11
references: 20888078
references: Nature. 2009 Jun 18;459(7249):996-9
references: 19494811
references: Age (Dordr). 2013 Oct;35(5):1675-90
references: 22986582
references: J Neuroinflammation. 2011;8:175
references: 22171672
references: BMC Med. 2012;10:35
references: 22502727
references: J Neurochem. 2007 Oct;103(1):145-56
references: 17573824
references: Biomed Res Int. 2014;2014:456937
references: 24719867
references: J Neuropathol Exp Neurol. 2008 Aug;67(8):773-83
references: 18648325
references: Neuroscience. 2013 Aug 15;245:148-56
references: 23608099
references: Circ Res. 2013 Feb 15;112(4):651-63
references: 23271793
references: Circ Res. 1994 Jun;74(6):1141-8
references: 8187280
references: Brain. 2012 Jan;135(Pt 1):124-38
references: 22189567
references: Aust N Z J Med. 2000 Feb;30(1):48-53
references: 10800878
references: Curr Opin Chem Biol. 2014 Jun;20:112-9
references: 24981829
references: Eur J Neurosci. 2004 Sep;20(6):1489-98
references: 15355316
references: Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H19-28
references: 23624625
references: Brain. 1999 Aug;122 ( Pt 8):1437-48
references: 10430830
references: PLoS Biol. 2010;8(9). pii: e1000479. doi: 10.1371/journal.pbio.1000479
references: 20877715
references: Circ Res. 2010 Apr 16;106(7):1253-64
references: 20185797
references: Arch Neurol. 2012 Dec;69(12):1632-8
references: 22964777
references: Trends Cell Biol. 2013 Apr;23(4):151-9
references: 23277088
references: Neurology. 2005 Dec 27;65(12):1863-72
references: 16237129
references: J Mol Biol. 2015 Feb 13;427(3):695-706
references: 25281900